Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Antonio Anzueto (San Antonio, United States of America). Should macrolides be given to all patients with community-acquired pneumonia? Pro argument. International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate

Member's Comments

No comment yet.

Related content which might interest you: Should steroids be used in community-acquired pneumonia? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 Should macrolides be given to all patients with community-acquired pneumonia? Con argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis Source: Eur Respir J 2007; 30: 525-531 Year: 2007 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Corticosteroids for community-acquired pneumonia: are we still there? Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis Source: Eur Respir J 2008; 31: 1068-1076 Year: 2008 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002 Should steroids be used in community-acquired pneumonia? Con argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017